Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.31 |
| ▸ | BRAF | P15056 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.30 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.30 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2820533 | 0.88 | L3MBTL1 (0.34) | MEN1RAB9AKMT2AL3MBTL1KDM4E | |
| SCHEMBL2821034 | 0.84 | PTGS2 (0.33) | MEN1RAB9AKMT2AL3MBTL1KDM4E | |
| SCHEMBL2819998 | 0.82 | P2RX7 (0.32) | BRAFL3MBTL1ALDH1A1PDE2A | |
| SCHEMBL2825212 | 0.78 | HPGD (0.34) | MEN1RAB9AKMT2AL3MBTL1KDM4E | |
| SCHEMBL2823483 | 0.75 | KDM4E (0.32) | MEN1RAB9AKMT2AL3MBTL1KDM4E | |
| SCHEMBL2822997 | 0.74 | L3MBTL1 (0.33) | MEN1RAB9AKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL2819937 | 0.74 | USP2 (0.38) | MEN1RAB9AKMT2AL3MBTL1KDM4E | |
| SCHEMBL2820687 | 0.72 | AR (0.33) | — | |
| SCHEMBL2823045 | 0.71 | KMT2A (0.33) | MEN1RAB9AKMT2AL3MBTL1KDM4E | |
| SCHEMBL2819903 | 0.71 | USP2 (0.36) | MEN1RAB9AKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1386914-B1 | HALOGENATED QUINOLINE DERIVATIVES AND ECTOPARASITE CONTROLLERS | MEIJI SEIKA KAISHA (JP) | 2010-10-27 | — | — | EP | disclosed |
| US-7022855-B2 | Halogen-substituted quinoline derivatives and ectoparasite control agent | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| EP-1559321-A1 | MIXED COMPOSITIONS FOR CONTROLLING PARASITIC INSECTS | MEIJI SEIKA KAISHA LTD. (JP) | 2005-08-03 | — | — | EP | disclosed |
| US-20040087618-A1 | Halogen-substituted quinoline derivatives and ectoparasite control agent | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-05-06 | — | — | US | disclosed |
| US-20040077602-A1 | Mixture composition for controlling ectoparasites | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1386914-A1 | HALOGENATED QUINOLINE DERIVATIVES AND ECTOPARASITE CONTROLLERS | MEIJI SEIKA KAISHA LTD. (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087618-A1 | Halogen-substituted quinoline derivatives and ectoparasite control agent | ATL3, RABL3, RAB5C | KDR 3790/4885BRAF 163/4885MEN1 3131/4885 |
| US-20040077602-A1 | Mixture composition for controlling ectoparasites | SF3A3, PEX3, HCN3 | KDR 3073/4885BRAF 51/4885MEN1 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.